Syndax Pharmaceuticals Inc. (SNDX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on cancer therapies. The company currently has two FDA-approved products: Revuforj (revumenib) for acute leukemia and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease (cGVHD). The company operates as a single segment and continues to advance clinical programs for additional indications.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenue | $37.96 million | $57.75 million | $3.50 million |
| Net Loss | $(71.85) million | $(156.69) million | $(140.46) million |
| Loss Per Share (Basic/Diluted) | $(0.83) | $(1.82) | $(1.65) |
| Cash & Investments | $517.86 million (as of June 30, 2025) | Includes $108.6M cash, $346.6M short-term, $62.6M long-term | |
| Operating Cash Flow | $(182.96) million (YTD) | $(155.19) million (YTD 2024) | |
| Debt (Royalty Financing) | $343.85 million (Net Liability) | Includes $19.4M current portion |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly to $37.96 million in Q2 2025 compared to $3.50 million in Q2 2024. This is driven by the commercial launch of Revuforj ($28.6M product revenue) and Niktimvo collaboration revenue ($9.4M).
- Expense Increases: Operating expenses rose to $107.3 million in Q2 2025 from $77.7 million in Q2 2024.
- R&D: Increased to $62.2 million (Q2 2025) from $48.7 million (Q2 2024), driven by clinical trial costs and milestone expenses ($5.0M for Revuforj sNDA submission).
- SG&A: Increased to $43.8 million (Q2 2025) from $29.1 million (Q2 2024), primarily due to commercialization headcount and stock-based compensation.
- Interest Expense: New royalty interest expense of $7.85 million was recognized in Q2 2025 related to the Royalty Pharma agreement executed in late 2024. No such expense existed in Q2 2024.
- Inventory Build: Inventory increased to $17.7 million from $0.4 million at year-end 2024, reflecting preparation for commercial sales.
Outlook, Guidance, and Risks
- Regulatory Milestones: The FDA granted Priority Review to the supplemental New Drug Application (sNDA) for Revuforj in mNPM1 AML, with a PDUFA target action date of October 25, 2025.
- Commercial Performance: Revuforj revenue grew 43% sequentially in Q2. Niktimvo achieved $36.2M in net revenue in Q2 (Syndax's share of profit was $9.4M), representing the first full quarter of U.S. launch.
- Liquidity: Management believes current cash, investments ($517.9M), and expected product revenue are sufficient to fund operations for the foreseeable future. No equity sales occurred under the ATM program in the first half of 2025.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, the ability to replicate clinical results, and the impact of the royalty financing agreement on future cash flows. Geopolitical tensions and supply chain disruptions are also noted as potential risks.
Investor Verification Checklist
- Revenue Recognition: Verify the sustainability of Revuforj sales growth and the specific terms of the 50/50 profit-sharing arrangement with Incyte for Niktimvo.
- Royalty Financing Impact: Assess the impact of the $350M Royalty Pharma deal, specifically the 13.8% royalty rate on U.S. Niktimvo sales and the $822.5M payment cap.
- Cash Burn Rate: Monitor the net cash used in operating activities ($183M YTD) against the $518M cash/investment balance to determine runway.
- Regulatory Timeline: Confirm the October 25, 2025 PDUFA date for the Revuforj mNPM1 AML indication and the potential for accelerated approval.
- Milestone Expenses: Track future contingent milestone payments due to Vitae (AbbVie) and UCB as clinical and commercial targets are met.